The coronavirus vaccine developed by Pfizer and BioNTech was able to combat a new variant that was rapidly circulating in Brazil, a new study has found.
The research published in the New England Journal of Medicine found that the engineered version of the virus, containing the same mutation carried on the spike protein as the highly contagious P1 variant first identified in Brazil, was effectively neutralised among people who were given the jab.
The new variants are observed to carry changes in the spike, which is used by the virus to enter the human cells. These changes, in turn, affects how transmissible the virus is and therefore, is the primary target of the many coronavirus vaccines.
Scientists from the two companies and the University of Texas Medical Branch said that the neutralising ability of the vaccine on the new variant was equivalent to the effect on the less contagious version of the virus from the last year.